Gaurav Shah
CIK 1725922 · CEO · last filed 2026-08-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RCKT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1040
NEW YORK, NY 10016
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RCKT | CEO | 1,254,935 | $2.28 | $2.86M | -$1.15M | 16 | 2026-08-20 |
| ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | CEO | 1,315,749 | $0.00 | $2.6K | -$1.70M | 23 | 2026-05-26 |
| Tourmaline Bio, Inc. (TALS) Delisted | Director | — | $27.20 | — | $0 | 2 | 2023-06-14 |
Recent Filings · Page 4 of 6
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-20 | ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | Mixed | +99,597 | -$228.6K | EDGAR |
| 2024-05-16 | RCKT | Notice (144) | −9,790 | -$228.6K | EDGAR |
| 2024-02-21 | ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | Mixed | +46,305 | -$604.9K | EDGAR |
| 2024-02-16 | RCKT | Notice (144/A) | −20,272 | -$604.9K | EDGAR |
| 2024-02-16 | RCKT | Notice (144) | −20,272 | -$604.9K | EDGAR |
| 2024-02-16 | ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | Exer (M) | −46,828 | $0 | EDGAR |
| 2023-11-16 | RCKT | Notice (144) | −4,627 | -$97.6K | EDGAR |
| 2023-11-16 | ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | Exer (M) | −7,979 | $0 | EDGAR |
| 2023-08-21 | ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | Sell (S) | −4,767 | -$73.8K | EDGAR |
| 2023-08-17 | RCKT | Notice (144) | −4,767 | -$73.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.